Innate Pharma (IPHA) Stock Price, News & Analysis

Company Overview

Innate Pharma S.A. is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company researches treatments designed to activate or enhance the immune system’s ability to recognize and eliminate tumor cells, with an emphasis on natural killer cells and other components of the innate immune system.

Its pipeline includes lacutamab, an antibody directed at KIR3DL2 that is being studied in certain forms of cutaneous T-cell lymphoma. Innate Pharma has also developed monalizumab, an antibody targeting the NKG2A immune checkpoint, through a collaboration with AstraZeneca. The company’s broader research portfolio includes additional antibody-based programs and immune-targeting approaches for oncology.

Founded in 1999, Innate Pharma is headquartered in Marseille, France, and serves the international biopharmaceutical market through research, clinical development and strategic partnerships. Its American Depositary Shares trade on the Nasdaq Capital Market under the symbol IPHA, while the company is also listed on Euronext Paris. Mondher Mahjoubi serves as chief executive officer.

Key Stats

• Today's Range: $1.48 to $1.51
• 50-Day Range: $1.43 to $2.27
• 52-Week Range: $1.17 to $2.71
• Volume: 5,395 shs
• Average Volume: 33,394 shs
• Market Capitalization: $167.58 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.67
• Consensus Rating: Moderate Buy

Innate Pharma Stock Analysis - MarketRank™

Innate Pharma scored higher than 74% of companies evaluated by MarketBeat, and ranked 232nd out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Innate Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 5 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Innate Pharma has a consensus price target of $6.67, representing about 344.4% upside from its current price of $1.50.

Amount of Analyst Coverage

Innate Pharma has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Innate Pharma are expected to grow in the coming year, from ($0.53) to ($0.45) per share.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.17% of the float of Innate Pharma has been sold short.

Short Interest Ratio / Days to Cover

Innate Pharma has a short interest ratio ("days to cover") of 2.64, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Innate Pharma has recently increased by 43.15%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Innate Pharma does not currently pay a dividend.

Dividend Growth

Innate Pharma does not have a long track record of dividend growth.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.94

News Sentiment

Innate Pharma has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Innate Pharma this week, compared to 2 articles on an average week.

MarketBeat Follows

2 people have added Innate Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Innate Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

31.89% of the stock of Innate Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

0.16% of the stock of Innate Pharma is held by institutions.

Company Calendar

• Today: 10/30/2026
• 2026 Stifel Healthcare Conference: 11/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:IPHA
• CIK: 1598599
• Web: www.innate-pharma.com
• Phone: 33-4-30-30-30-30
• Fax: N/A
• Employees: 163
• Year Founded: 1999

Price Target and Rating

• Average Price Target for Innate Pharma: $6.67
• High Price Target: $9.00
• Low Price Target: $4.00
• Potential Upside/Downside: +344.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.60
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $10.19 million
• Price / Sales: 16.45
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.26) per share
• Price / Book: -5.77

Miscellaneous

• Outstanding Shares: 111,720,000
• Free Float: 76,092,000
• Market Cap: $167.58 million
• Optionable: Not Optionable
• Beta: 0.72